Medistep Healthcare (NSE:MEDISTEP) Current Deferred Revenue: ₹0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MEDISTEP Medistep Healthcare Ltd NSE:MEDISTEP
23 GF Score
Price ₹22.50
! 3 Warning Signs
View Full Analysis

What is Medistep Healthcare Current Deferred Revenue?

Medistep Healthcare NSE:MEDISTEP -3.85% 23 Current Deferred Revenue is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:MEDISTEP with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Medistep Healthcare's current deferred revenue for the quarter that ended in Mar. 2026 was ₹0.0 Mil.

Medistep Healthcare Current Deferred Revenue Related Terms

Medistep Healthcare Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Medistep Healthcare's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistep Healthcare Current Deferred Revenue Chart

Medistep Healthcare Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
0.00 0.00 0.00 0.00 0.00

Medistep Healthcare Quarterly Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:MEDISTEP
23GF Score
Medistep Healthcare Ltd NSE:MEDISTEP
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₹0.0 Mil mean?
Medistep Healthcare (NSE:MEDISTEP) has a Current Deferred Revenue of ₹0.0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Medistep Healthcare and its competitors.
Is Medistep Healthcare's Current Deferred Revenue too high?
Medistep Healthcare's current Current Deferred Revenue is ₹0.0 Mil. Overall, Medistep Healthcare has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Medistep Healthcare's Current Deferred Revenue compare to MCK and COR?
Medistep Healthcare's Current Deferred Revenue of ₹0.0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Distribution company?
A good Current Deferred Revenue depends on the Medical Distribution industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Medistep Healthcare and its competitors. Medistep Healthcare's current Current Deferred Revenue is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistep Healthcare stock overvalued right now?
Medistep Healthcare (NSE:MEDISTEP) has a current Current Deferred Revenue of ₹0.0 Mil. The current Current Deferred Revenue is ₹0.0 Mil. Medistep Healthcare's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Medistep Healthcare (NSE:MEDISTEP), the current Current Deferred Revenue is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medistep Healthcare Business Description

Address National Highway 8, 05, S. No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Near A-One Hotel, Narol Gam, Narol, Daskroi, Ahmadabad, GJ, IND, 382405
Medistep Healthcare Ltd operates in the pharmaceutical and healthcare product sectors. Its business includes manufacturing intimate care and hygiene products such as sanitary pads, as well as nutraceutical products like energy powders. The company also trades a variety of pharmaceutical, surgical, and medical equipment products. Medistep Healthcare's operations focus mainly on the western region of India, particularly in Gujarat. Its Core business activity is divided into the following categories: a) Trading of Pharmaceutical & Surgical products, b) Trading & Manufacturing of Nutraceuticals and Intimate care & hygiene products. The company generates the majority of its revenue from Trading and distribution.
23GF Score

Get the complete analysis for NSE:MEDISTEP

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹22.50
Price